Add BrightSurf on Google Email

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

Researchers at Fox Chase Cancer Center have provided a detailed assessment of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging. The study found that upstaging rates associated with delays are relatively small and consistent with prior data.

SourceTemple University Health System·JournalAnnals of Surgical Oncology·TypeData/statistical analysis·DateJul 24, 2025

NTU Singapore and Oxford scientists reveal how cells repair toxic DNA damage linked to cancer and premature ageing

Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.

SourceNanyang Technological University·JournalNucleic Acids Research·TypeExperimental study·DateJul 21, 2025

New research in JNCCN offers reassurance about localized prostate cancer prognosis

A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJul 10, 2025

Stratifying the immune landscape of tongue cancer

Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.

SourceInstitute of Science Tokyo·JournalCancer Immunology Immunotherapy·TypeExperimental study·DateMay 27, 2025

Dr. Adithya Hari joins Pennington Biomedical as physician/nuclear oncologist, adds to center’s strategic expansion of cancer metabolism program

Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.

UT Health San Antonio-led research discovers a way to slow or block recurrence of glioblastoma

Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.

SourceUniversity of Texas Health Science Center at San Antonio·JournalEMBO Molecular Medicine·TypeExperimental study·DateMar 26, 2025

Delay of more than 42 days for breast cancer surgery raises death risk for certain subtypes, University of Oklahoma study finds

Patients with hormone receptor-positive and HER2-negative breast cancers face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery. Delayed surgery increases the patient's risk exponentially, with risks of death increasing by 21%, 79%, and 183% at 60, 90, and 120 days, respectively.

SourceUniversity of Oklahoma·JournalBreast Cancer Research·TypeData/statistical analysis·DateMar 24, 2025

TNIP1 knockdown induces the growth arrest and apoptosis of breast cancer cells by activating the NF-κB pathway

This study investigates TNIP1's role in regulating cell proliferation and apoptosis in breast cancer. TNIP1 knockdown was found to induce growth arrest and activate the NF-κB pathway, leading to increased apoptosis in breast cancer cells. The findings highlight TNIP1 as a crucial marker for breast cancer therapies.

SourceXia & He Publishing Inc.·JournalOncology Advances·DateMar 19, 2025

Targeted alpha therapy: a breakthrough in treating refractory skin cancer

A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.

SourceChiba University·JournalEuropean Journal of Nuclear Medicine and Molecular Imaging·TypeExperimental study·DateMar 12, 2025

Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds

A new study suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer. Researchers found that both stress-related neurotransmitters and obesity-related hormones activate a protein called CREB, which is linked to cancer cell growth.

SourceUniversity of California - Los Angeles Health Sciences·JournalMolecular Cancer Research·DateMar 10, 2025

Study reveals hope for immunotherapy as prostate cancer treatment

Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...

SourceUniversity of Arizona Health Sciences·JournalCancer Immunology Research·TypeExperimental study·DateMar 4, 2025